200 related articles for article (PubMed ID: 8678496)
21. [Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study].
Tominaga T; Abe O; Izuo M; Nomura Y
Gan To Kagaku Ryoho; 1993 Jan; 20(1):79-90. PubMed ID: 8422189
[TBL] [Abstract][Full Text] [Related]
22. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
23. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
Bottini A; Berruti A; Brizzi MP; Bersiga A; Generali D; Allevi G; Aguggini S; Bolsi G; Bonardi S; Tondelli B; Vana F; Tampellini M; Alquati P; Dogliotti L
Endocr Relat Cancer; 2005 Jun; 12(2):383-92. PubMed ID: 15947110
[TBL] [Abstract][Full Text] [Related]
25. [A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer].
Takatsuka Y; Yayoi E; Miyauchi K; Aikawa T; Maeura Y; Hirai T; Kotsuma Y
Gan To Kagaku Ryoho; 1992 May; 19(5):631-6. PubMed ID: 1533755
[TBL] [Abstract][Full Text] [Related]
26. [Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer].
Nomura Y; Tashiro H; Shirouzu M; Takayama T
Gan To Kagaku Ryoho; 1996 Mar; 23(4):439-45. PubMed ID: 8678495
[TBL] [Abstract][Full Text] [Related]
27. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen].
Nomura Y; Tominaga T; Abe O; Izuo M; Ogawa N
Gan To Kagaku Ryoho; 1993 Feb; 20(2):247-58. PubMed ID: 8434963
[TBL] [Abstract][Full Text] [Related]
28. [A case report of advanced breast cancer with remarkable response to chemoendocrine therapy (CTF + MPA)].
Yokota T; Fujii T; Roppongi T; Kanno K; Ogata T
Gan To Kagaku Ryoho; 1998 Apr; 25(5):739-42. PubMed ID: 9571973
[TBL] [Abstract][Full Text] [Related]
29. [Endocrine therapy for advanced or recurrent breast cancer].
Sonoo H; Kurebayashi J
Gan To Kagaku Ryoho; 2001 Jul; 28(7):909-16. PubMed ID: 11478139
[TBL] [Abstract][Full Text] [Related]
30. [Intra-arterial infusion chemotherapy for advanced or recurrent breast cancers].
Okazaki M; Okazaki A; Masuoka H; Toda K; Yamada T; Okazaki Y; Asaishi K; Hirata K; Narimatsu E
Gan To Kagaku Ryoho; 1995 Apr; 22 Suppl 1():94-101. PubMed ID: 7747999
[TBL] [Abstract][Full Text] [Related]
31. [A study on the efficacy of combination chemoendocrine therapy consisting of cyclophosphamide, adriamycin, UFT, and tamoxifen for advanced or recurrent breast cancer].
Yamaguchi S; Fukuda M; Ota T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1145-52. PubMed ID: 10431580
[TBL] [Abstract][Full Text] [Related]
32. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
33. [A case of breast cancer with multiple metastases successfully treated by medroxyprogesterone acetate with intermittent intra-arterial infusion low-dose chemotherapy to hepatic metastasis].
Kusama M; Kaise H; Nakayama S; Oota D; Shimizu H; Aoki T; Koyanagi Y
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2243-7. PubMed ID: 11142170
[TBL] [Abstract][Full Text] [Related]
34. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M
Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004
[TBL] [Abstract][Full Text] [Related]
35. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
36. Sequential hormone therapy with medroxyprogesterone acetate for 7, 12-dimethylbenz [alpha] anthracene-induced rat mammary tumors.
Iino Y; Ishikawa H; Izuo M; Takikawa H
Jpn J Clin Oncol; 1989 Mar; 19(1):45-50. PubMed ID: 2522157
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells.
Sica G; Lama G; Iacopino F; Angelucći C; Della Cuna GR; Marchetti P
Anticancer Res; 1991; 11(6):2099-102. PubMed ID: 1776846
[TBL] [Abstract][Full Text] [Related]
38. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
[TBL] [Abstract][Full Text] [Related]
40. [A comparative study between low-dose and high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer--in relation to dose, serum concentration and response. Osaka Breast Cancer Research Group].
Furukawa J; Yayoi E; Takatsuka Y; Aikawa T; Maeura Y; Kobayashi T; Miyauchi K; Kotsuma Y
Gan To Kagaku Ryoho; 1997 May; 24(7):815-21. PubMed ID: 9170519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
